Gainers
- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering.
- Brickell Biotech, Inc. (NASDAQ:BBI) gained 119% to $0.2550.
- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) jumped 29.6% to $1.0891. HTG Molecular Diagnostics highlighted a publication in Frontiers Medicine.
- Akouos, Inc. (NASDAQ:AKUS) surged 29% to $6.35.
- Iterum Therapeutics plc (NASDAQ:ITRM) gained 29% to $0.2520.
- 2U, Inc. (NASDAQ:TWOU) gained 25% to $11.62. Indian online education provider Byju’s offered to buy 2U for $15 a share in cash, valuing the edtech company at more than $1 billion, reported Bloomberg, citing a person familiar with the matter.
- Agenus Inc. (NASDAQ:AGEN) surged 23% to $2.2750. Agenus announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer.
- Revelation Biosciences, Inc. (NASDAQ:REVB) shares rose 21.4% to $0.5980. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares gained 20.5% to $2.4350 after the company announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations.
- Integrated Media Technology Limited (NASDAQ:IMTE) shares gained 20.5% to $3.4850.
- Athersys, Inc. (NASDAQ:ATHX) gained 18.4% to $0.3105.
- Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares jumped 16% to $0.4065.
- AdTheorent Holding Company, Inc. (NASDAQ:ADTH) gained 14.8% to $2.87.
- G Medical Innovations Holdings Ltd (NASDAQ:GMVD) shares surged 13.6% to $0.60.
- Exicure, Inc. (NASDAQ:XCUR) surged 13.3% to $0.1450.
- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) gained 12.7% to $5.09.
- Catalyst Biosciences, Inc. (NASDAQ:CBIO) gained 11.5% to $1.6850. Catalyst Biosciences announced plan to distribute cash to stockholders.
- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) surged 9.2% to $1.54.
- LiveOne, Inc. (NASDAQ:LVO) rose 5.8% to $0.8037 after reporting better-than-expected Q4 results.
- Beyond Air, Inc. (NASDAQ:XAIR) rose 5.2% to $6.09 after the company posted a narrower FY22 loss. The FDA also approved Beyond Air’s LungFit PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newborn or PPHN).
